NLS Drug Development Pharma

As Swedish contract manufacturer APL reforms the organization 75 staff members are being made redundant.

Shareholders in Diamyd Medical AB representing a majority of the votes in the company have reached an agreement to distribute the parent company’s excess cash to the shareholders and to convert all shares to series B shares with equal voting power. The shares in the subsidiary Diamyd Therapeutics AB shall be distributed to the shareholders […]

Dako announced in mid-February that the company has entered into a collaboration agreement with Pfizer in the field of companion diagnostics. The agreement constitutes a legal framework for various collaboration projects between the two companies, covering research, development and commercialization as well as advisory services. “We are extremely excited to partner with Pfizer, a company […]

AstraZeneca’s facility Snäckviken in Södertälje has been acquired by Acturum and will from now on be called BiovationPark Telge. The facility will host SP process development, Scania, Campus Telge and around 20 small research companies. Besides laboratories and offices, Acturum will install 5000 laboratory instruments at the facility. Astra will also hand over 15 drug […]

The two companies have entered an agreement regarding a preclinical program for a potential novel treatment of respiratory diseases (OX-CLI). Orexo grants to AstraZeneca rights to conduct further preclinical research and evaluation of compounds in Orexo’s OX-CLI program. AstraZeneca also has an option to acquire the compounds pertaining to the program, subject to a full […]

Orphan drugs are a classification of medicines for rare diseases. The market for those medicines is relatively small due to the low number of patients. Since development of pharmaceuticals is expensive, special incentives have been created to encourage pharma and biotech companies to conduct research. As a result a special orphan status was developed in […]